In a recent study at Brigham and Women’s Hospital and Harvard Medical School, researchers found that 4 out of 5 patients with heart failure with reduced ejection fraction (HFrEF) could be considered for treatment with dapagliflozin.
This is an sodium-glucose co-transporter-2 (SGLT2) inhibitor.
The study is published in JAMA Cardiology. One author is Muthiah Vaduganathan, M.D., M.P.H.
While SGLT2 inhibitors were initially developed for the management of type 2 diabetes, dapagliflozin is the first SGLT-2 inhibitor to be approved for use for heart failure, irrespective of diabetes status.
In the study, the team analyzed data from over 150,000 patients hospitalized for HFrEF at over 400 hospital centers.
They found that 80% of patients in the registry met the FDA criteria for HF treatment with dapagliflozin;
A similarly high proportion of patients with type 2 diabetes and without type 2 diabetes met eligibility criteria;
Advanced kidney disease was the most common reason for not being a dapagliflozin candidate;
Treatment candidates identified in the GWTG-HF registry shared many clinical characteristics with participants enrolled in DAPA-HF,3 the pivotal trial that established the efficacy and safety of dapagliflozin in HFrEF.
The findings support the view that the SGLT2 inhibitors are now established as a new pillar of care for patients with heart failure.
The team says doctors must now rapidly translate this knowledge to practice to improve patient outcomes.
Copyright © 2021 Knowridge Science Report. All rights reserved.
